FASEB J. Cell Migration Consortium
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rubba, P.
Right arrow Articles by Faccenda, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rubba, P.
Right arrow Articles by Faccenda, F.

The FASEB Journal, Vol 7, 1491-1498, Copyright © 1993 by The Federation of American Societies for Experimental Biology


REVIEWS

Noninvasive ultrasound techniques versus angiography for monitoring drug-induced changes of the arterial walls

P Rubba and F Faccenda
Institute of Internal Medicine and Diseases of Metabolism, Medical School, University Federico II, Naples, Italy.

Even though angiographic studies contribute to understanding the process of atherosclerosis progression/regression in humans, they have several important limitations. The number of participants in all the studies is small and those who accept the invasive vascular investigation are highly selected patients, in most instances in an advanced stage of cardiovascular disease. Furthermore, arteriography provides the image of the vessel lumen but no information on the vessel wall. Noninvasive methods can describe the characteristics of the arteries with regard to morphology (intima-media thickness, surface irregularities, areas of calcification) and the hemodynamic correlates of vascular lesions. No single methodology describes all aspects of the disease process. However, B-mode ultrasound imaging gives information on the vessel wall, whereas Doppler mainly describes the hemodynamic consequences of arterial disease. Before any noninvasive methodology can be adopted for a clinical trial, extensive validation data (preferably using pathology rather than angiography as a "gold standard"), and accurate information on reproducibility and on inter-, intraobserver variability, should be available. Also, quantitative details on the natural history of the disease and on the potential of intervention, as evaluated by the specific methodology to be used, should be known.





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1993 by The Federation of American Societies for Experimental Biology.